Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen Ltd. (CGEN) announced updated data from its Phase 1 study of COM701, an investigational antibody targeting PVRIG, reporting a 66.7% disease control rate when combined with Opdivo®. Key results included a confirmed complete response in a previously unresponsive patient and ongoing durable responses over a year in several patients. The company plans to expand the study to include patients with ovarian, breast, endometrial, and colorectal cancers. Compugen aims to evaluate dual and triple blockade regimens, enhancing the potential of its innovative immunotherapy approach.
Compugen Ltd. (CGEN) announced an expanded clinical collaboration with Bristol Myers Squibb to evaluate COM701, a first-in-class anti-PVRIG antibody, in a Phase 1b cohort study. This study will combine COM701 with Opdivo® (nivolumab) and is set to begin in Q2 2021. Initial results from dose escalation show preliminary antitumor activity. The study will focus on patients with ovarian, breast, endometrial, and colorectal cancers, aiming to provide insights on treatment efficacy through monotherapy, dual, and triple combination therapies.
Compugen Ltd. (Nasdaq: CGEN) will release its fourth quarter and full year 2020 financial results on February 25, 2021, before U.S. markets open. A conference call will follow at 8:30 AM ET for management to discuss the results and provide updates. Compugen specializes in cancer immunotherapy and predictive target discovery, with key products COM701 and COM902 currently in Phase 1 clinical studies. The company is headquartered in Israel and has offices in South San Francisco, CA, with shares traded on Nasdaq and the Tel Aviv Stock Exchange.
Compugen Ltd. (Nasdaq: CGEN) announces participation in several virtual investor conferences. Key events include the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:40 AM ET, the Jefferies Virtual Healthcare Conference on November 18, 2020, at 5:35 AM ET, and the Evercore ISI HealthCONx Conference on December 1, 2020, at 9:40 AM ET. Live webcasts will be available on the Compugen website, with replays accessible post-event. The company is focused on cancer immunotherapy, with its lead product COM701 in Phase 1 clinical studies.
Compugen Ltd. (NASDAQ: CGEN) reported its Q3 2020 financial results, revealing a net loss of $7.8 million, or $0.09 per share, an increase from $6.5 million, or $0.10 per share, in Q3 2019. R&D expenses rose to $5.5 million from $4.3 million due to ongoing clinical studies. A noteworthy milestone was the initiation of a Phase 1/2 study for the anti-PVRIG antibody, COM701, in combination with Bristol Myers Squibb's Opdivo® and an investigational TIGIT antibody. Compugen's cash reserves reached approximately $133 million, significantly up from $44 million at year-end 2019.
Compugen Ltd. (CGEN) has received a new patent from the China National Intellectual Property Administration for COM902, an immuno-oncology therapeutic antibody targeting TIGIT. This patent extends the protection for COM902 beyond existing patents in the U.S. and Europe and covers its composition for cancer treatment. The patent is valid until at least August 2037. COM902 is currently in a Phase 1 clinical trial, showing potential to enhance T cell responses against tumors when combined with PD-1 inhibitors. This development reflects Compugen's commitment to expanding its immuno-oncology pipeline.
Compugen Ltd. (Nasdaq: CGEN) announced new research data on October 27, 2020, suggesting that PVRIG may enhance T cell priming and infiltration into tumors, potentially improving cancer immunotherapy outcomes. Presented at the 2020 TIGIT Therapies Digital Summit, findings indicate that PVRIG inhibition could benefit patients with unresponsive tumors. The data highlight PVRIG's role in T cell activation and its expression alongside TIGIT and PD-1, indicating that targeting this pathway could provide new treatment options.
Compugen Ltd. (Nasdaq: CGEN) announced it will release its third quarter 2020 financial results on November 5, 2020, before U.S. markets open. A conference call will take place at 8:30 AM ET to review the results and provide corporate updates. Compugen is a leader in cancer immunotherapy, with products like the first-in-class anti-PVRIG antibody COM701 under Phase 1 study, along with COM902 targeting TIGIT. The company focuses on predictive target discovery for therapeutics in immuno-oncology.
Compugen Ltd. (Nasdaq: CGEN) has announced the appointment of Dr. Nils Lonberg to its Scientific Advisory Board. Dr. Lonberg, a leader in immuno-oncology with over 30 years of experience, will replace Dr. Charles Drake, who is leaving to pursue a new role in the pharmaceutical industry. Compugen's CEO, Anat Cohen-Dayag, highlighted Dr. Lonberg's contributions to cancer treatment and his potential to enhance the company's efforts in immunotherapy. The company currently has ongoing clinical studies for its lead product candidate, COM701, an anti-PVRIG antibody.
Compugen Ltd. (CGEN) has initiated its Phase 1/2 study, dosing the first patient for a triple combination therapy using COM701, Opdivo®, and BMS-986207. This clinical trial aims to assess the safety and efficacy of targeting PVRIG and TIGIT alongside PD-1 pathways to enhance anti-tumor responses in patients with advanced solid tumors. The study will enroll approximately 100 patients and includes a biomarker-driven approach focusing on ovarian and endometrial cancers. Compugen's CEO expressed optimism about the partnership with Bristol Myers Squibb and the potential to improve immunotherapy options.